Primary Biliary Cholangitis Drug Pipeline: 13 Assets by Phase

How many primary biliary cholangitis drugs are in each phase of development?

Douglas Insights counts 4 primary biliary cholangitis candidates in Phase III, 31% of the 13 assets in development; Phase II holds 6 and Phase I holds 3.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each primary biliary cholangitis asset appears in exactly one row. The 30 trials still recruiting or running carry 38% of the 80 registered trials in scope.

Which approved primary biliary cholangitis medicines are still in trials?

1 medicines already on the market are still being tested in primary biliary cholangitis Phase IV trials; Ursodeoxycholic Acid has the most, with 14 registered trials.

Post-approval primary biliary cholangitis trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many primary biliary cholangitis trials are recruiting patients now?

14 primary biliary cholangitis trials are recruiting patients and 5 more have not started recruiting yet, out of 80 interventional trials in scope; together they make up 24% of the trial base.

Terminated, suspended and withdrawn primary biliary cholangitis trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the primary biliary cholangitis pipeline?

Intercept Pharmaceuticals leads the primary biliary cholangitis pipeline with 2 candidates; the top 5 sponsors hold 54% of the 13 assets, and 11 sponsors run at least one.

Industry sponsors lead 48 of the 80 primary biliary cholangitis trials (60%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the primary biliary cholangitis pipeline?

Mechanism and drug-type classification for the 13 primary biliary cholangitis candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What primary biliary cholangitis trial readouts are coming next?

4 primary biliary cholangitis candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many primary biliary cholangitis readouts fall in each quarter?

6 primary biliary cholangitis candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 2, due in Q1 2027.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most primary biliary cholangitis trials?

United States hosts the most primary biliary cholangitis trials, with sites in 36 of the 80 studies (45%); trials in scope run in 51 countries in all.

A multinational primary biliary cholangitis trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are primary biliary cholangitis drugs being tested?

36 of the 80 primary biliary cholangitis trials (45%) have a site in the United States, 27 (34%) in Europe and 29 (36%) in China; 9 of the 13 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational primary biliary cholangitis trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the primary biliary cholangitis pipeline since the last update?

This is the first edition of the primary biliary cholangitis pipeline count, dated 4 Oct 2026. The next refresh is due by 2 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the primary biliary cholangitis pipeline?

Douglas Insights read 80 interventional trials registered on ClinicalTrials.gov for the conditions "Liver Cirrhosis, Biliary", "primary biliary cholangitis" and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 13 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the primary biliary cholangitis pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage